borderline significanceP = 0.057
Notably, the proportion of patients treated with RAAS inhibitors who did not progress to ESRD was higher than the proportion who did (88.6 vs 73.1%, P = 0.057, although with borderline significance).
Notably, the proportion of patients treated with RAAS inhibitors who did not progress to ESRD was higher than the proportion who did (88.6 vs 73.1%, P = 0.057, although with borderline significance).